Establishment Labs announces new partnerships to expand breast aesthetics technology

The medtech company Establishment Labs has entered into agreements with four partners in Europe and a second partner chain in Japan to expand its breast aesthetics technology.

The company, which offers a portfolio of femtech solutions for breast health and breast aesthetics, has developed a “minimally invasive” breast aesthetics experience to improve the appearance of the breasts.

The technology, called Mia Femtech, aims to shape the breast up one to two cups in a 15-minute procedure without the need for general anaesthesia.

“Our global rollout of Mia Femtech continues, and we are pleased to announce our first European partners in Sweden, Switzerland, and Spain, as well as an additional chain in Japan,” said Juan José Chacón-Quirós, the company’s founder and CEO.

“We expect to partner with many more centres with a focus on creating premium experiences with broad appeal.

“Mia is opening breast aesthetics to a new group of consumers and the strong interest in partnering with us demonstrates the potential of Mia to dramatically expand our markets.

“We look forward to many more announcements on Mia over the coming weeks and months.”

In Stockholm, Establishment Labs has already partnered with Nordiska Kliniken, one of Scandinavia’s leading clinics in plastic surgery and aesthetic treatments.

In Switzerland, the company is working with Leman Aesthetic Clinic in Geneva and Clinic Utoquai in Zurich while in Barcelona it is collaborating with Clínica Planas.

Joe Clinic, a medical aesthetics chain in Japan, will also begin to offer Mia at its Tokyo and Osaka locations.

“Mia Femtech will define a new premium aesthetic category with great potential for expanding the market,” said Javier Planas, CEO of Clínica Planas.

“We are excited to once again be at the forefront of innovation and excellence.”

Sam Besara, CEO of Nordiska Kliniken, said: “As leaders in plastic surgery, we are proud to introduce Mia Femtech as the coming evolution in breast aesthetics.

“Building Nordiska Kliniken has always been about innovating and this is the next natural step in our journey of being market leaders.”

Mia Femtech is not yet commercially available in the European Union and the United States.